Sonnet BioTherapeutics Holdings Inc Stock

$1.01

2.54% yesterday

Nasdaq, Sep 18, 09:39 pm CET

ISIN

US83548R1059

Symbol

SONN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Sonnet BioTherapeutics Holdings Inc Stock price

$1.00

-4,963.96 99.98% 5Y

Nasdaq, Closing price Wed, Sep 18 2024

+0.02 1.52%

ISIN

US83548R1059

Symbol

SONN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$5.12m
Enterprise Value	$1.72m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	28.67
P/S ratio (TTM) P/S ratio	85.33
P/B ratio (TTM) P/B ratio	1.96
Revenue growth (TTM) Revenue growth	-67.76%
Revenue (TTM) Revenue	$60.00k
EBIT (operating result TTM) EBIT	$-12.28m
Free Cash Flow (TTM) Free Cash Flow	$-10.00m
Cash position	$3.55m
EPS (TTM) EPS	$-3.02
P/E forward	negative
P/S forward	102.40
EV/Sales forward	34.40
Short interest	0.87%

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Get Started for Free Today

Sonnet BioTherapeutics Holdings Inc Stock Analysis

Unlock Scores for Free

??

2 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast:

2x Buy

100%

More details on Analyst Estimates Including Price Targets

2 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Sonnet BioTherapeutics Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter Annually

Assets

Jun '24
Current assets	5.13 5.13
Cash	3.55 3.55
Claims	0.52 0.52
Inventories	- -
Other current assets Other current assets Current assets	1.05 1.05

Fixed assets	0.67 0.67
Property, plant and equipment	0.17 0.17
Financial assets	- -
Intangible Assets	- -
Other fixed assets Other assets Fixed assets	0.50 0.50


Total Assets	5.80 5.80

Liabilities

Jun '24
Equity	2.62 2.62

Debt capital	3.18 3.18
Current liabilities	3.11 3.11
Non-current liabilities	0.07 0.07


Total Capital	5.80 5.80

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Sonnet BioTherapeutics Holdings Inc Stock News

Neutral

GlobeNewsWire

●

about 12 hours ago

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold' tumors ‘hot' Topline safety data of SB101 Phase 1 study expected by Q4 2024 PRINCETON, NJ, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the completion of enrol...

Neutral

GlobeNewsWire

●

14 days ago

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that it will participate in the Virtual Investor Closing Bell Series on Monday, September 9, 2024, at 4:00 PM ET.

Neutral

GlobeNewsWire

●

about one month ago

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15 fusion protein, for solid tumor immunotherapy

More Sonnet BioTherapeutics Holdings Inc News

Company Profile

Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded on April 1, 2020 and is headquartered in Princeton, New Jersey.

Head office	United States
CEO	Pankaj Mohan
Employees	12
Founded	2011
Website	www.sonnetbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now